Sector: Healthcare | Industry: Medical Equipment, Supplies & Distribution |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 25651 Atlantic Ocean Drive LAKE FOREST CA 92630 |
Tel: | 1-626-3037902 |
Website: | https://www.staar.com |
IR: | See website |
Key People | ||
Thomas G. Frinzi Chairman of the Board, President, Chief Executive Officer | Patrick F. Williams Chief Financial Officer | Warren Foust Chief Operating Officer |
James E. Francese Senior Vice President - Commercial Operations, North America and APAC | Robert Studholme Senior Vice President - Operations | Keith Holliday Chief Technology Officer |
Scott D. Barnes Chief Medical Officer | Samuel J. Gesten Chief Legal Officer, Corporate Secretary |
Business Overview |
STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems used to deliver the lenses into the eye. These lenses provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. The Company is a manufacturer of lenses used worldwide in corrective or refractive surgery. It sells its products in approximately 75 countries, with direct distribution in Japan, Germany, Spain, the United States, Canada, the United Kingdom, and Singapore, with a combination of direct distribution and independent distribution in China, Korea, India, France, Benelux, and Italy. The Company markets and sells ICLs for refractive surgery to treat myopia (nearsightedness) as its EVO family of lenses. The Company's EVO family of lenses includes its EVO ICL, EVO+ ICL, and EVO Visian ICL. The Company also markets and sells an ICL lens to treat hyperopia (farsightedness), which is called Visian ICL. |
Financial Overview |
For the fiscal year ended 29 December 2023, STAAR Surgical Co revenues increased 13% to $322.4M. Net income decreased 46% to $21.3M. Revenues reflect ICLs segment increase of 18% to $319.4M, China segment increase of 25% to $185.6M, Others segment increase of 3% to $81.2M. Net income was offset by General and administrative - Balancing increase of 33% to $60.2M (expense), Marketing and selling - Balancing value increase of 24% to $57.1M (expense). |
Employees: | 1,056 as of Dec 29, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $2,116M as of Dec 29, 2023 |
Annual revenue (TTM): | $322.42M as of Dec 29, 2023 |
EBITDA (TTM): | $33.53M as of Dec 29, 2023 |
Net annual income (TTM): | $21.35M as of Dec 29, 2023 |
Free cash flow (TTM): | -$3.59M as of Dec 29, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 48,865,875 as of Feb 21, 2024 |
Index Membership: | S&P 600 Small Cap |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |